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A high intake of sugars has been linked to diet-induced health problems. The fructose content in sugars consumed may also affect
health, although the extent to which fructose has a particularly significant negative impact on health remains controversial. The
aim of this narrative review is to describe the body’s fructose management and to discuss the role of fructose as a risk factor
for atherosclerosis, type 2 diabetes, and obesity. Despite some positive effects of fructose, such as high relative sweetness, high
thermogenic effect, and low glycaemic index, a high intake of fructose, particularly when combined with glucose, can, to a larger
extent than a similar glucose intake, lead to metabolic changes in the liver. Increased de novo lipogenesis (DNL), and thus altered
blood lipid profile, seems to be the most prominent change. More studies with realistic consumption levels of fructose are needed,
but current literature does not indicate that a normal consumption of fructose (approximately 50–60 g/day) increases the risk of
atherosclerosis, type 2 diabetes, or obesity more than consumption of other sugars. However, a high intake of fructose, particularly
if combined with a high energy intake in the form of glucose/starch, may have negative health effects via DNL.
1. Introduction
Sugars are important sources of energy in our diet, and a
high intake of sugars has increasingly been identified as a
considerable cause of major diet-induced health problems,
namely, atherosclerosis, type 2 diabetes, and obesity [1–
4]. An increased intake of sugar sweetened beverages in
particular has been associated with these health problems in
many epidemiological studies [5–7].Themain constituents of
sugars are fructose and glucose, which can be present either
alone or in combination, although most commonly fructose
is mixed 50 : 50 with glucose. The ratio of glucose : fructose
in the diet has been argued to be important for some of the
effects of sugars [8, 9].Thus, it is important to study the effects
of fructose and glucose together, but also it is important to
study the effects of fructose alone. Fructose has been claimed
to be of benefit because itmay aid glycemic control [10, 11], but
also it has been claimed to bemore harmful than other sugars,
especially with regard to the development of atherosclerosis,
type 2 diabetes, and obesity [8].
Fructose is found in a variety of foods. In table sugar, it is
bound to glucose to form the disaccharide sucrose, whereas
in honey it occurs in monosaccharide form. In fruit, berries,
and vegetables, fructose occurs in both monosaccharide and
disaccharide forms. Measured as intake from caloric sweet-
eners in USA, fructose intake was rather stable throughout
the fifties and sixties but increased from the seventies until
the end of the nineties, after which intake has declined [12].
The average American fructose intake was estimated to be
49 g per day in 2004 [13]. In Norway, the average daily intake
of fructose can be estimated to be approximately 56 g/day,
based on data from the Norwegian Directorate of Health’s
survey of consumption patterns [14] and composition data
[15]. Globally, the main source of fructose is sucrose, which
constitutes >90% of the energizing sweeteners used in the
world [16]. In some countries, such as USA and Japan,
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high-fructose corn syrup (HFCS) is also an important source
of fructose. HFCS is a mixture of fructose and glucose in
different concentrations. It can contain up to 90% fructose
[17], but the dominating concentration of fructose is 42%
or 55% in commercial products [9]. In USA, consumption
of HFCS increased sharply from 1970 until 1999, but it has
declined since then [12, 18].
This review paper aims to describe how fructose, com-
pared with other sugars, is managed by the body, thus
clarifying the impact of fructose on atherosclerosis, type 2
diabetes, and obesity.
2. Materials and Methods
The review is based on scientific peer-reviewed papers
obtained using a nonsystematic search of the databases
PubMed and Web of Science. The first step in the selection
of literature was to identify the relevant keywords to search
for in these databases. Various combinations of the fol-
lowing keywords were used: “fructose,” “glucose,” “sucrose,”
and “sugar” combined with “metabolism,” “insulin resis-
tance,” “overweight,” “obesity,” “relative sweetness,” “absorp-
tion capacity,” “glycemic index,” “de novo lipogenesis,” “ther-
mogenesis,” “type 2 diabetes,” and “appetite regulation.”
The next step in the selection process consisted of inclu-
sion or exclusion of papers based on the relevance to the
study’s aim. Through this initial selection process, both orig-
inal and review papers were included. The reference lists of
the papers were thoroughly studied to discover any possibly
relevant papers that were not included. As far as possible,
only original papers and reviews based on controlled trials
and mechanistic studies were included. Unless otherwise
specified, the results presented and discussed in this paper are
statistically significant, and the experiments were conducted
with a control group. Although animals may metabolize
fructose differently from humans, animal studies have been
included when found relevant, for example, due to lack of
human studies. One possible limitation in this study lies in
the nonsystematic nature of the search strategy, resulting in
the possibility that relevant papers were not considered.
3. The Body’s Fructose Management
3.1. Absorption. Although there is some uncertainty about
the mechanisms of fructose absorption, most of fructose
seems to be absorbed by facilitated transport in the jejunum
by the fructose transporter GLUT5 [18–20]. The body
has limited capacity to absorb pure fructose, and intake
of fructose can therefore lead to malabsorption [20–24].
Malabsorption of fructose results in bacterial fermentation,
which leads to formation of short-chain fatty acids (acetate,
propionate, and butyrate) and gases (hydrogen, methane,
and carbon dioxide) [25, 26]. These processes can affect the
motility of the intestine and cause various symptoms such
as abdominal pain, bloating, and altered stool [27]. A large
individual variation in absorption capacity for fructose has
been observed. When fructose is consumed as a single oral
dose, the maximum absorption capacity has been shown to
vary between 5 and 50 g [28]. Several factors seem to affect
this capacity, such as age and health [27, 29, 30], but of the
dietary factors the presence of glucose is the most important
[20, 23]. A significant increase in fructose absorption has
been shown when fructose is coingested with equal amounts
of glucose [21, 31].There is still uncertainty about how glucose
increases absorption capacity for fructose, but itmay amongst
others be due to an effect of glucose on the presence of
fructose transporters [20]. Fructose does not appear in any
fruit or vegetable without glucose [15]. Evolutionarily, this
may explain why humans do not have the ability to absorb
large amounts of pure fructose.
3.2. Metabolism. After absorption, fructose is transported by
the portal vein to the liver, where it is effectively absorbed
by liver cells [32], resulting in only small amounts entering
the systemic circulation. The concentration of fructose in
the blood is therefore only about 0.01mmol/L, unlike that of
glucose which is approximately 5.5mmol/L [33]. Metabolism
of fructose thus occurs primarily in the liver, but fructosemay
also be metabolized by enterocytes. In a study of pigs, it was
shown that intestinal lactate production from fructose could
account for 12% of absorbed fructose [34], but the functional
significance of intestinal metabolism of fructose in humans
remains unknown [18]. Bjorkman and Felig [35] also showed
that infused fructose (48.6 g fructose in liquid form infused
intravenously) was metabolized in the kidneys in humans
who had fasted for 60 hours. Despite the artificially high
blood fructose level, that study still shows that the kidneys
have a relatively large capacity to metabolize fructose. It has
been shown that GLUT5 is expressed in the membrane of fat,
kidney, muscle, and brain cells [32, 36], but, due to very low
levels of fructose in the blood, negligible amounts of fructose
are probably metabolized in these tissues [9, 18].
As discussed above, the liver will metabolize a large
majority of the ingested fructose, compared to only about
15–30% of ingested glucose [37, 38]. Most of the reactions
in liver fructolysis are the same as those occurring in
glycolysis, but fructose enters at a later stage in the glycolytic
reaction chain than glucose [39]. Thus, fructose avoids the
main control step in glycolysis, the phosphofructokinase
step, which is tightly regulated by the energy status of the
cell. The first step in fructolysis is the phosphorylation of
fructose by fructokinase to fructose 1-phosphate. Unlike
the phosphofructokinase in glycolysis, this enzyme is not
inhibited by ATP [40]. The enzyme is considered virtually
unregulated and, even when the liver’s energy status (ATP)
is high, the fructokinase will metabolize fructose to fructose
1-phosphate. Furthermore, fructose 1-phosphate is cleaved
to dihydroxyacetone phosphate and glyceraldehyde by the
enzyme aldolase B. Glyceraldehyde may be phosphorylated
by triose kinase, with ATP as the phosphate donor, to form
the glycolytic intermediate glyceraldehyde 3-phosphate [41].
After these steps, the carbon atoms from fructose follow the
glycolytic steps.
Bypassing the phosphofructokinase step makes the flow
of fructose carbon atoms through the biochemical pathways
less controlled than for glucose. In this way, the liver will
metabolize fructose in an unlimited way, as opposed to the
case of glucose. This will influence the type and amount of
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metabolic products produced by the liver and is the main
reason why fructose and glucose have different metabolic
effects.
In the liver, fructose can enter metabolic pathways: it
can be oxidized, converted to glucose (and glycogen), or
converted to lactic acid, or enter de novo lipogenesis (DNL).
After an overnight fast, approximately 50% of the fructose
eaten as an oral dose of approximately 30–70 g is converted
to glucose via gluconeogenesis [42]. Others have shown
that after a similar fructose intake about 45% is oxidized;
however, this includes both direct fructose oxidation and
oxidation of glucose and lactic acid formed from fructose
[43]. Another metabolic fate of fructose is to form lactic
acid, but this seems to occur only at high fructose intakes
[44–48]. The ingestion of 72 g fructose is the lowest amount
that has been experimentally demonstrated to result in lactic
acid formation [49]. Intake of fructose may also lead to
formation of fatty acids via DNL. The diet composition may
influence the distribution of fructose. Theytaz et al. [50]
showed that coingestion of glucose with fructose decreased
oxidation and gluconeogenesis from fructose carbon atoms.
Intake of fructose together with glucose thus seems to affect
the metabolic fate of fructose. To some degree, this effect
may be due to higher insulin secretion after intake of glucose
compared to fructose [51]. Insulin will, amongst others,
decrease glucose production from fructose [52], and insulin
will also stimulate DNL [53]. The extent to which fructose
enters DNL is central to the health effects of fructose.
3.3. De Novo Lipogenesis (DNL). DNL is the metabolic
pathway that transforms surplus nonfat energy into fat by
synthesis of fatty acids from acetyl-CoA [54]. The liver is the
primary site of DNL, but DNL can also occur in lactating
mammary glands and adipose tissue. Key lipogenic enzymes
are present in adipose tissue, but to what degree adipose
tissue contributes to the total DNL seems to be unclear.
Although some data indicate that DNL in adipose tissue is of
little importance [55–57], it has also been shown that it may
play a more significant role [58], especially after ingestion of
large amounts of carbohydrates [59, 60]. Some controversy
exists regarding the capacity of the liver to carry out de novo
lipogenesis in humans [60, 61], although a high capacity has
been demonstrated in several experiments [62, 63].
As a result of the metabolic difference between glucose
and fructose, a higher percentage of fructose compared to
glucose can be converted to fat in the liver via DNL [63].
This has been shown in a number of animal and human
studies, in which these sugars have been consumed in equal
quantities under similar experimental conditions [63–66].
The greater potential of fructose to stimulate DNL is the
main reason why fructose has been portrayed as particularly
harmful. As described earlier, the liver absorbs most of
the ingested fructose, and fructose metabolism bypasses the
main control step in glycolysis, which means that a greater
proportion of fructose, compared with glucose, is available
for DNL. A normal diet, however, provides 3 to 5 times
more glucose than fructose [12, 67], and this may influence
the practical relevance of this metabolic difference. If, for
example, glucose intake is very high, the liver may need to
handle larger amounts of glucose than fructose. At two points
in liver fructolysis, intermediates can enter lipid synthesis
[9]. Fructose is converted to dihydroxyacetone phosphate,
an intermediate in equilibrium with glycerol 3-phosphate,
which forms the basis for the glycerol in triglycerides and
phospholipids. Meanwhile, a large proportion of fructose
carbons are metabolized directly to pyruvic acid and then
acetyl-CoA. On metabolism of a large amount of fructose
to acetyl-CoA, the amount of acetyl-CoA may exceed the
citric acid cycle capacity of mitochondria. High levels of
fructose may thus act as a nonregulated source of hepatic
acetyl-CoA, which is a substrate that can enter DNL [9]. In
addition, a high intake of fructose seems to stimulate gene
expression and activity of lipogenic enzymes in the liver
[40, 41, 66, 68]. Recently, fructose has also been shown to
give a higher increase in fibroblast growth factor 21 (FGF21)
than glucose. FGF21 is a hormone involved in glucose and
lipid homeostasis [69], and high levels of FGF21 seem to be
associated with metabolic disease [70].
It is clear that a high intake of fructose will cause a
significant increase in DNL activity [71]. However, there is a
paucity of knowledge about the effect of a normal fructose
intake on this activity [72]. No research seems to have been
conducted to assess the minimum amount or individual
range of fructose that must be eaten to obtain a significant
increase in DNL, which among others may be due to diffi-
culties in quantifying DNL. In fact, measurement of hepatic
DNL must be considered semiquantitative [54, 73]. Chong
et al. [73] found that 13C-labelled fructose contributed only
0.4% of the triglycerides in very-low-density lipoproteins
(VLDLs) in men. This was measured 6 hours after eating
a meal of 0.5 g fat/kg body weight and 0.75 g fructose/kg
body weight after an overnight fast. The small increase in
triglyceride levels in the blood after a fructose intake may
be a result of delayed triglyceride secretion. Incorporation
of carbon from 13C-labelled fructose in VLDLs will not
always reflect DNL, because some of the newly synthesized
fatty acids will have delayed secretion [74, 75]. The level of
DNL activity after fructose intake seems to vary significantly
among individuals [76–78], and it also seems to vary during
the day [79, 80].
Excessive intake of fructose, and hence increased DNL,
may increase the risk of disease, because it may potentially
cause both increased cholesterol levels in the blood and
accumulation of fat in the liver [81]. In several animal studies,
fat accumulation in the liver has been demonstrated after a
high intake of fructose [82, 83], althoughmost human studies
have failed to demonstrate such an effect [84–86]. In fact,
Chiu et al. [87] concluded, based on a systematic review
with meta-analysis of controlled feeding trials, that fructose
does not increase lipid content in liver when isocalorically
exchanged for other carbohydrates. However, they pointed
out that fructose ingested in large doses can raise liver lipid
content, an effect thatmay be due to excess energy rather than
fructose per se. Bravo et al. [88] conducted a study where
participants consumed sucrose or HFCS for ten weeks at
different levels of intake. In the study, fructose consumed as a
part of a normal diet did not promote increased liver lipid
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content even at high intakes (90th percentile consumption
level). In a study referred to by Rippe and Angelopoulos
[89], no increase in liver fat was observed after consumption
of HFCS or sucrose at levels up to 30% of energy for ten
weeks. However, Maersk et al. [90] found that intake of
1 L sucrose-sweetened soft drink per day for six months
increased liver lipids in overweight participants compared
with intake of same amount of milk, diet cola, and water.
This may illustrate that the combination of fructose and
glucose, as in sucrose, can lead to increased level of liver
lipids. However, it is not possible to conclude that this is an
effect of fructose, since there was no glucose control group
in this study. Johnston et al. [91] found no difference in liver
triglyceride level between overweight participants that ate a
hypercaloric high-fructose or high-glucose diet. The authors
concluded that this result indicates that the hypercaloric
state rather than macronutrient composition is important
for the accumulation of liver lipids. Carbohydrate-induced
accumulation of fat in the liver can lead to nonalcoholic
fatty liver disease (NAFLD) [92]. However, it is still unclear
if fructose via increased DNL is particularly conducive to
NAFLD [93]. The effect of fructose on lipid accumulation
is thus unclear, but the effect of fructose on the blood lipid
profile seems to be better documented.
4. Atherosclerosis
It appears that high fructose intake can create an unfavorable
lipid profile in blood via DNL [94]. The main product of
DNL is palmitic acid [95], a fatty acid specifically shown to
increase the risk of atherosclerosis [96]. Fatty acids formed
by DNL will mainly be packed in VLDLs delivered into the
bloodstream. This may, in turn, increase the level of low-
density lipoproteins (LDLs) in the blood. In several studies,
fructose has to a greater extent than glucose increased blood
levels of triglycerides [51, 65, 97, 98] and LDLs [65, 99–
103]. Aeberli et al. [104] showed that fructose increased the
small dense LDLs, the type of LDLs that may in particular be
linked to cardiovascular risk [105]. The level of high-density
lipoproteins (HDLs) in blood does not seem to be affected
by fructose [100, 101]. In most studies, an intake of fructose
>100 g/day has been necessary to observe the adverse effects
on lipid profiles [51, 65, 85, 98, 100, 106–108]. However, in a
recent study by Aeberli et al. [109], a daily intake of about 77 g
fructose and 34 g glucose for 3 weeks resulted in increased
levels of total cholesterol and LDLs in the blood of healthy
young men, compared with a daily intake of approximately
109 g glucose and 28 g fructose over the same time period.
The fact that both groups also ingested an unknown amount
of starch and the fact that food intake was not controlled
reduce the solidity of these results. Maersk et al. [90] found
that intake of 50 g fructose per day together with 50 g glucose
could have a negative effect on blood triglyceride level. The
lack of a control group ingesting glucose makes it difficult
to conclude that this is an effect of fructose. Conversely,
Lowndes et al. [110] found no negative effect on lipid profile
in overweight or obese individuals consuming HFCS or
sucrose incorporated in a eucaloric diet for ten weeks at
levels corresponding to the 25th and 50th percentiles of adult
fructose consumption. Using the current knowledge, it does
not appear that the consumption of moderate amounts of
fructose (<50 g/day) alone will result in an unfavorable blood
lipid profile [86, 111].
Due to the insignificant levels of fructose in peripheral
blood, as described above, only glucose has the potential to
be a substrate for DNL in adipose tissue. Although DNL
in adipose tissue seems to be small as earlier discussed,
glucose will, because of its presence in blood and by raising
blood insulin level, probably to a higher extent than fruc-
tose, stimulate DNL in adipose tissue. Intake of glucose, in
amounts that exceed the total capacity for glycogen storage
and glucose oxidation, may thus increase DNL in adipose
tissue more than the same amount of fructose. While fat
formed in the liver has to be transported as lipoproteins
in blood, this is avoided if the fat is formed directly in
adipose tissue. Considering known negative health effects of
lipoprotein residues, DNL occurring in adipose tissuemay be
preferable comparedwithDNL in the liver.Thismay illustrate
a metabolic difference between glucose and fructose when
consuming large amounts of sugars.
Another possible difference between fructose and glucose
on risk factors for atherosclerosis is the effect of these sugars
on blood uric acid level. Increased uric acid level has been
associated with atherosclerosis in epidemiological studies,
but the causality is uncertain [112–114]. Fructose appears to
increase uric acid levels in the blood to a higher extent than
glucose, especially at high intakes and when consumed as
excess energy [86, 115, 116]. Intake of 0.5 g fructose/kg body
weight is the lowest quantity shown to result in uric acid
formation [117]. An increased blood level of uric acid can
theoretically lead to elevated blood pressure because uric acid
inhibits an enzyme in the endothelial cells of the arteries
called endothelial nitric oxide synthase (eNOS). Activated
eNOS leads to increased production of nitric oxide (NO),
an important vasodilator. Thus, inhibition of eNOS may lead
to vasoconstriction. Although only 0.5 g fructose/kg body
weight has been shown to give uric acid formation and
increased uric acid level theoretically could increase blood
pressure, results from studies of the effect of fructose on
blood pressure are very inconsistent [65, 72, 118, 119]. An
average intake of fructose does not seem to lead to increased
blood pressure [111, 120, 121]. The lack of causal link between
uric acid level and atherosclerosis makes it difficult to draw
conclusions on this effect of fructose.
5. Type 2 Diabetes
A high intake of sugar-sweetened beverages, with fructose as
one of the major types of monosaccharides, has been associ-
ated with development of type 2 diabetes [5, 122]. Although
this association does not prove causation, it is important
to study the role of fructose in the development of type 2
diabetes. Central to the understanding of type 2 diabetes is
the effect of nutrients on blood glucose homeostasis. Fructose
must be converted to glucose in the liver to cause an increase
in blood glucose level. As the conversion takes time and only
a portion of the fructose will form glucose, fructose increases
blood glucose less than similar levels of glucose [51]. Thus,
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the glycemic index for fructose is only 23 [10]. This, together
with lack of stimulation of the pancreatic 𝛽 cells [123], gives
lower insulin secretion after intake of fructose compared
with glucose [51, 124, 125]. These effects are positive because
they contribute to blood glucose homeostasis. Additionally,
moderate amounts of fructose have been shown to have
positive effects on glycemic control [86, 126, 127]. However,
it is claimed that fructose may also contribute negatively
to blood glucose homeostasis by causing insulin resistance
in the liver [9]. There is evidence that a high intake of
fructose can cause insulin resistance in animals [128, 129],
but several human studies have failed to demonstrate such
an association [103, 130–132]. The operational definition of
insulin resistance or sensitivity seems unclear, and many
different methods have been used to measure it [133]. Thus,
it is difficult to compare studies of insulin resistance. In
human studies, in which fructose has been reported to cause
insulin resistance, the daily intake of fructose has been as
high as 110 g [109], approximately 250 g [134], 80 g [135], and
138 g [65]. This may indicate that the fructose intake must
be high to potentially cause insulin resistance [86]. In the
studies by Aeberli et al. [109], Stanhope et al. [65], and Beck-
Nielsen et al. [134], total food intake was not controlled.
Thus, the observed effect of fructose may also have been
caused by differences in food intake between the control
and experimental groups. In all the studies, in which insulin
resistance has been shown, fructose was eaten together with
glucose or starch, so the observations could also be the
result of a combination of fructose and glucose. A number
of hypotheses on how fructose can cause insulin resistance
in the liver have been proposed. Lipid accumulation in
the liver [136–138], metainflammation [83], and oxidative
stress [139] are, either via inhibitory phosphorylation of the
insulin receptor or the signalingmolecules involved in insulin
signaling, possible mechanisms for fructose-induced insulin
resistance [9]. However, there are too few studies in humans
and these are too divergent to be able to conclude firmly
that there is a link between the consumption of fructose and
insulin resistance. More long-term studies in which the daily
intake of fructose is moderate are needed.
6. Obesity
It is debatable whether fructose is less satiating than other
sugars and thus can contribute to obesity through a high food
intake. In a study by Page et al. [92], magnetic resonance
(MR) images were taken of human brains after giving 75 g of a
fructose or glucose drink. Glucose, but not fructose, reduced
activity (regional cerebral blood flow) in the hypothalamus in
the areas involved in energy regulation and reward systems;
this is probably an indicator of satiety and may indicate that
fructose is less satiating than glucose. Fructose will also to
a lesser extent than glucose increase blood levels of insulin
[51], leptin [51, 140], gastric inhibitory polypeptide [141], and
glucagon-like peptide-1 [92], while at the same time it will
attenuate levels of ghrelin less [51]. Although these hormonal
effectsmay indicate that fructose is less satiating than glucose,
this has not been confirmed in studies of the ability of fructose
to satiate. In such studies, it has been shown that fructose
has a greater appetite-reducing effect than glucose, when
intake occurs before a meal [142, 143], or that there is no
difference in the effects on appetite between fructose and
glucose [144, 145].Therefore, the effect of fructose on appetite
remains unclear.
Although it is conceivable that fructose, via lack of
stimulation of satiety signals, could contribute to obesity,
fructose has several properties that act against obesity. As
previously mentioned, the small intestine has a limited
capacity to absorb fructose. This can lead to malabsorption
at least if large amounts are consumed and consumption
occurs without glucose-providing nutrients. Malabsorption
of fructose will make less fructose enter the bloodstream
and thus less energy will be available to the cells. In this
way the malabsorption will act against obesity. It has also
been shown in numerous studies that fructose has a greater
thermogenic effect than glucose [46, 146–148]. This means
that the body uses more energy after eating fructose rather
than glucose, so less energy will be available to be stored as
fat. The relative sweetness of fructose is also greater than for
glucose and sucrose [149, 150]. Although this will decrease
with increasing temperature [151, 152], the high relative
sweetness allows smaller amounts of fructose than glucose
and sucrose to be used to achieve a particular sweetness in
most applications. On the basis of these properties, it does
not appear that fructose is more fattening than other sugars.
This also agrees with experimental studies of the relationship
between fructose intake and obesity in animals [153, 154] and
humans [65, 86, 106, 155].
7. Substrate Oxidation
It has been proposed that fructose can inhibit lipid oxidation
[146]. For liver lipid oxidation this is logical, because the
liver acquires energy from fructose and thus does not need
to oxidize fat. Fructose can also increase DNL. It would not
be expedient to form and break down fat simultaneously
in the liver, and increased levels of malonyl-CoA (due to
active DNL) will inhibit 𝛽-oxidation [41, 156]. It would also
be logical for fructose to increase total body lipid oxidation
more than glucose due to fructose’s smaller contribution as
an extrahepatic energy source. In some studies, however,
fructose has been shown to increase the respiration quotient





than glucose. This indicates that fructose to a higher degree
than glucose reduces total body lipid oxidation and increases
total body carbohydrate oxidation. Blaak and Saris [158]
conducted a study in which participants ate 75 g fructose,
starch, or glucose after a 12-hour fast in a crossover study.
Fructose resulted in a significantly larger increase in the RQ,
measured 6 hours after ingestion, than both glucose and
starch. Tappy et al. [146] also showed a greater increase in
RQ 4 hours after ingestion of 75 g fructose, compared with
similar healthy participants eating 75 g glucose. Schwarz et
al. [46] conducted a similar study (75 g fructose/glucose)
with the same result. These results may be explained by the
fact that fructose, more than glucose, enters DNL under
specific conditions. Due to the fact that RQ varies for different
substrates (e.g., 1 for carbohydrates and 0.7 for fats), RQ is
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used to determine the source of substrate oxidation [159].





. Simultaneous occurrence ofDNL and carbohydrate
oxidation can lead to RQ values greater than 1 [159]. An
increased RQ caused by DNL can, therefore, be misinter-
preted as reduced lipid oxidation and increased carbohydrate
oxidation. Such amisinterpretationmay have occurred in the
studies described above. Thus the effect of fructose on total
body substrate oxidation remains unclear.
8. Discussion
The distribution of fructose into metabolic pathways, espe-
cially DNL, is of key importance to the health effects of
fructose. The distribution varies with the amount of fructose
consumed, the duration of fructose exposure, the composi-
tion of diet/meal, and whether the measurement took place
postprandially, after absorption, or under fasting conditions.
Individual physiological, enzymatic, and endocrine factors
are also important. Diet composition and the amount of fruc-
tose eaten and absorbed will be the focus of this discussion.
Malabsorption of fructose will affect the amount of
fructose absorbed and can thus be an important confounding
factor in studies in which factors that affect absorption
capacity have not been taken into account [39]. Truswell et al.
[21] showed that intake of 50 g fructose led to malabsorption
in over 50% of the study participants. The results of studies
in which fructose is malabsorbed can thus be inaccurate
due to individual differences in the absorption capacity of
fructose. As the small intestine has a large absorption capacity
for glucose and a limited one for fructose, it is problematic
to compare fructose with glucose as the sole carbohydrate
source. In future studies, this should be controlled for, for
example, by using the hydrogen breath test to assess fructose
malabsorption.
The composition of diet and especially the amount of
glucose/starch may have influence on the health effects of
fructose. As fructose is present with glucose in most food
products, it is more practical and relevant to look at the
effects of fructose and glucose together than the effects of
fructose alone. A larger increase in DNL after eating fructose
and glucose together (50 : 50 glucose : fructose) rather than
the same amount as pure glucose has been shown [63].
Eating glucose with fructose is likely to affect fructose’s health
effects by stimulating the flow of fructose to DNL [50]. This
effect could be due to both increased absorption capacity for
fructose when coingested with glucose and therefore greater
availability of fructose carbon atoms going towards DNL and
increased blood insulin levels when glucose is present in
the diet. Insulin stimulates DNL directly and indirectly by
inhibiting other important metabolic pathways for fructose,
such as gluconeogenesis. It is also plausible that glucose will
compete with fructose as an energy source for enterocytes
and hepatic cells, thus making more fructose available for
DNL. Coingestion of glucose with fructose has been shown
to decrease oxidation and gluconeogenesis from fructose
carbon atoms [50]. Thus, it appears that the combination
of fructose and glucose is particularly unfortunate, although
fructose is not a prerequisite for DNL. It is unclear howmuch
glucose/starch must be included with fructose for this effect
to be significant.
The amount of fructose consumed seems to be of great
importance to the effects of fructose on health. The negative
health effects of fructose have mainly been demonstrated
at high intakes, and several studies have found an average
intake of fructose to cause no health problems [12, 110, 111,
160]. Although the average daily intake of fructose is 50–
60 g/day, someof the populationwill consume larger amounts
[161, 162], so the negative health effects of fructose may be
relevant at least for a proportion of the population. Many of
the current studies are poorly suited to determine health risks
of fructose because (a) the fructose intakes are unrealistically
high, (b) fructose is given in isolation and not mixed with
other carbohydrates as in practice, and/or (c) the studies
are conducted on animals. Differences between human and
animal physiology limit their applicability to humans. There
is a need for more human studies under conditions more
similar to the way fructose is normally consumed. Such
studies, particularly related to DNL, will be necessary to
understand the effects of a normal fructose intake.The effects
of fructose on triglyceride and cholesterol levels in the blood,
fat accumulation in liver, and insulin signaling all seem
to be linked to the extent to which fructose enters DNL.
Surprisingly, there have been no satisfactory studies to assess
the proportion of fructose that enters DNL at different levels
of intake. Such studies should be carried out and should
include intake of both pure fructose and fructose together
with glucose.
It is also important to note that, despite the metabolic dif-
ference between glucose and fructose, glucose consumption
far exceeds fructose consumption in the human diet [12].This
quantitative aspect must be considered when comparing the
health effects of glucose and fructose.
9. Conclusion
Although there is a paucity of published literature regarding
physiological effects of fructose in humans, current literature
does not indicate that a normal consumption of fructose
(approximately 50–60 g/day) increases the risk of atheroscle-
rosis, type 2 diabetes, or obesity more than consumption of
other sugars. However, a high intake of fructose, particularly
if combined with a high energy intake in the form of
glucose/starch, may have negative health effects via DNL.
More studies are clearly needed, particularly studies under
more realistic consumption levels of fructose.
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